Prof. Dr. Beat Thürlimann
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Curigliano G, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2019; 30:1181.
Jul 1, 2019De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Jul 1, 2019Ann Oncol 2019; 30:1181
Curigliano G, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H J, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial
Denkert C, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner B, Dietel M, Fasching P, Colleoni M, Blohmer J, Mehta K, Budczies J, Regan M, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua M, Solbach C, Thürlimann B, Viale G. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Res Treat 2019; 176:557-568.
May 7, 2019Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial
May 7, 2019Breast Cancer Res Treat 2019; 176:557-568
Denkert Carsten, Müller Volkmar, Klauschen Frederick, Ataseven Beyhan, Engels Knut, Kammler Roswitha, Pfitzner Berit M, Dietel Manfred, Fasching Peter A, Colleoni Marco, Blohmer Jens-Uwe, Mehta Keyur, Budczies Jan, Regan Meredith M, Loibl Sibylle, Dell'Orto Patrizia, von Minckwitz Gunter, Mastropasqua Mauro G, Solbach Christine, Thürlimann Beat, Viale Giuseppe
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98
Kensler K, Brown M, Viale G, Colleoni M, Thürlimann B, Kammler R, Hazra A, Schnitt S, Pyle M, Baker G, Heng Y, Regan M, Tamimi R. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. Breast Cancer Res 2019; 21:30.
Feb 22, 2019Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98
Feb 22, 2019Breast Cancer Res 2019; 21:30
Kensler Kevin H, Brown Myles, Viale Giuseppe, Colleoni Marco, Thürlimann Beat, Kammler Roswitha, Hazra Aditi, Schnitt Stuart J, Pyle Michael E, Baker Gabrielle M, Heng Yujing J, Regan Meredith M, Tamimi Rulla M
Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer
Hoemme A, Driessen C, Früh M, Thürlimann B, Wälti T, von Kameke A, Lehner C, Strasser F, Krähenbühl S, Haschke M, Barth H, Jörger M. Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer Chemother Pharmacol 2019; 83:763-774.
Jan 25, 2019Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer
Jan 25, 2019Cancer Chemother Pharmacol 2019; 83:763-774
Hoemme Alexander, Driessen Christoph, Früh Martin, Thürlimann Beat, Wälti Thomas, von Kameke Alexander, Lehner Claudia, Strasser Florian, Krähenbühl Stephan, Haschke Manuel, Barth Holger, Jörger Markus
Management of HER2-Positive Early Breast Cancer
Steger G, Luftner D, Stöger H, Thürlimann B, Untch M. Management of HER2-Positive Early Breast Cancer. Breast Care (Basel) 2018; 13:453-455.
Dec 5, 2018Management of HER2-Positive Early Breast Cancer
Dec 5, 2018Breast Care (Basel) 2018; 13:453-455
Steger Günther, Luftner Diana, Stöger Herbert, Thürlimann Beat, Untch Michael
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Ruhstaller T, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber R, Coates A, Goldhirsch A, Thürlimann B, Regan M, Veyret C, Del Mastro L, Giobbie-Hurder A, Colleoni M, Jensen M, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen E, Gladieff L, Bonnefoi H, Harvey V, Spazzapan S, Tondini C, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol 2018:JCO1800440.
Nov 26, 2018Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Nov 26, 2018J Clin Oncol 2018:JCO1800440
Ruhstaller Thomas, Simoncini Edda, Gianni Lorenzo, Rochlitz Christoph, Kralidis Elena, Zaman Khalil, Jassem Jacek, Piccart-Gebhart Martine, Di Leo Angelo, Gelber Richard D, Coates Alan S, Goldhirsch Aron, Thürlimann Beat, Regan Meredith M, Veyret Corinne, Del Mastro Lucia, Giobbie-Hurder Anita, Colleoni Marco, Jensen Maj-Britt, Ejlertsen Bent, de Azambuja Evandro, Neven Patrick, Láng István, Jakobsen Erik Hugger, Gladieff Laurence, Bonnefoi Hervé, Harvey Vernon J, Spazzapan Simon, Tondini Carlo, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, André F, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E, Burstein H, Baselga J, Bergh J, Bonnefoi H, Garber J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S, Curigliano G. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2018; 29:2153.
Oct 1, 2018De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Oct 1, 2018Ann Oncol 2018; 29:2153
Xu B, Osborne K C, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C-S, Hayes D F, Harbeck N, Pagani O, Partridge A H, Pritchard K, Whelan T J, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E J T, Ro J, Goodwin P, Gulluoglu B, André F, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E P, Burstein H J, Baselga J, Bergh J, Bonnefoi H, Garber J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S Y, Curigliano G
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer
Van Asten K, Van Calster B, Christodoulou E, Vergote I, Thürlimann B, Viale G, Regan M, Giobbie-Hurder A, Paridaens R, Smeets A, Weltens C, Van Limbergen E, Floris G, Wildiers H, Brouckaert O, Jongen L, Olbrecht S, Slembrouck L, Neven P. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. Oncologist 2018
Aug 31, 2018Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer
Aug 31, 2018Oncologist 2018
Van Asten Kathleen, Van Calster Ben, Christodoulou Evangelia, Vergote Ignace, Thürlimann Beat, Viale Giuseppe, Regan Meredith M, Giobbie-Hurder Anita, Paridaens Robert, Smeets Ann, Weltens Caroline, Van Limbergen Erik, Floris Giuseppe, Wildiers Hans, Brouckaert Olivier, Jongen Lynn, Olbrecht Siel, Slembrouck Laurence, Neven Patrick
Impact of subtypes and comorbidities on breast cancer relapse and survival in population-based studies
Ess S, Mousavi M, Frick H, Rohrmann S, Ortelli L, Bordoni A, Konzelmann I, Rapiti E, Neyroud I, Bouchardy C, Herrmann C, Thürlimann B. Impact of subtypes and comorbidities on breast cancer relapse and survival in population-based studies. Breast 2018; 41:151-158.
Jul 30, 2018Impact of subtypes and comorbidities on breast cancer relapse and survival in population-based studies
Jul 30, 2018Breast 2018; 41:151-158
Ess Silvia M, Mousavi Mohsen, Frick Harald, Rohrmann Sabine, Ortelli Laura, Bordoni Andrea, Konzelmann Isabelle, Rapiti Elisabetta, Neyroud Isabelle, Bouchardy Christine, Herrmann Christian, Thürlimann Beat
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial
Luen S, Regan M, Colleoni M, Viale G, Thürlimann B, Hackl W, Dolan S, JeBailey L, Demanse D, Biasi O, Dell'Orto P, Kammler R, Savas P, Lee C, Asher R, Loi S. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial. JAMA Oncol 2018
Jun 14, 2018Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial
Jun 14, 2018JAMA Oncol 2018
Luen Stephen J, Regan Meredith M, Colleoni Marco, Viale Giuseppe, Thürlimann Beat, Hackl Wolfgang, Dolan Sinead, JeBailey Lellean, Demanse David, Biasi Olivia Maria, Dell'Orto Patrizia, Kammler Roswitha, Savas Peter, Lee Chee Khoon, Asher Rebecca, Loi Sherene
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
Dowsett M, Sestak I, Regan M, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol 2018; 36:1941-1948.
Apr 20, 2018Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
Apr 20, 2018J Clin Oncol 2018; 36:1941-1948
Dowsett Mitch, Sestak Ivana, Regan Meredith M, Dodson Andrew, Viale Giuseppe, Thürlimann Beat, Colleoni Marco, Cuzick Jack
Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies
Herrmann C, Vounatsou P, Thürlimann B, Probst-Hensch N, Rothermundt C, ess s. Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies. BMJ Open 2018; 8:e017806.
Mar 14, 2018Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies
Mar 14, 2018BMJ Open 2018; 8:e017806
Herrmann Christian, Vounatsou Penelope, Thürlimann Beat, Probst-Hensch Nicole, Rothermundt Christian, ess silvia
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
Wapnir I, Gelber S, Coates A, Gelber R, Rastogi P, Regan M, Wolmark N, Aebi S, International Breast Cancer Study Group, NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group, Geyer C, Mamounas E, Thürlimann B, Price K, Anderson S, Robidoux A, Martín M, Nortier J, Paterson A, Rimawi M, Láng I, Baena-Cañada J, Breast International Group. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol 2018; 36:1073-1079.
Feb 14, 2018Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
Feb 14, 2018J Clin Oncol 2018; 36:1073-1079
Wapnir Irene L, Gelber Shari, Coates Alan S, Gelber Richard D, Rastogi Priya, Regan Meredith M, Wolmark Norman, Aebi Stefan, International Breast Cancer Study Group, NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group, Geyer Charles E, Mamounas Eleftherios P, Thürlimann Beat, Price Karen N, Anderson Stewart J, Robidoux Andre, Martín Miguel, Nortier Johan W R, Paterson Alexander H G, Rimawi Mothaffar F, Láng István, Baena-Cañada José Manuel, Breast International Group
Vitamin D levels in Swiss breast cancer survivors
Baumann M, Templeton A, Ruhstaller T, Riesen W, Mark M, Klingbiel D, Hochstrasser A, Dietrich D, Dani S, Thürlimann B. Vitamin D levels in Swiss breast cancer survivors. Swiss Med Wkly 2018; 148:w14576.
Jan 29, 2018Vitamin D levels in Swiss breast cancer survivors
Jan 29, 2018Swiss Med Wkly 2018; 148:w14576
Baumann Michael, Templeton Arnoud J, Ruhstaller Thomas, Riesen Walter F, Mark Michael Thomas, Klingbiel Dirk, Hochstrasser Andreas, Dietrich Daniel, Dani Sergio Ulhoa, Thürlimann Beat
Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al
Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E, Burstein H, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S, Bonnefoi H, Curigliano G. Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al. Ann Oncol 2017
Sep 25, 2017Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al
Sep 25, 2017Ann Oncol 2017
Xu B, Osborne K C, Orecchia R, Morrow M, Karlsson Per, Jiang Z, Jassem J, Khaled H, Huober J, Huang C-S, Hayes D F, Harbeck N, Pagani O, Partridge A H, Pritchard K, Whelan T J, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E J T, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, Winer E P, Burstein H J, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S Y, Bonnefoi H, Curigliano G
Absence of Evidence is not Evidence of Absence: The Case of Non-Inferiority
Klingbiel D, Thürlimann B, Brauchli P, von Moos R. Absence of Evidence is not Evidence of Absence: The Case of Non-Inferiority. Ann Oncol 2017
Aug 31, 2017Absence of Evidence is not Evidence of Absence: The Case of Non-Inferiority
Aug 31, 2017Ann Oncol 2017
Klingbiel D, Thürlimann Beat, Brauchli P, von Moos R
Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
Zweifel M, Sessa C, Schoenfeld W, Tapia C, Brauchli P, Hawle H, Pilop C, Rothgiesser K, Bigler M, Pagani O, von Moos R, Weder P, Riniker S, Thürlimann B. Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. Endocr Connect 2017; 6:549-556.
Aug 16, 2017Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
Aug 16, 2017Endocr Connect 2017; 6:549-556
Zweifel Martin, Sessa Cristiana, Schoenfeld Wolfgang, Tapia Coya, Brauchli Peter, Hawle Hanne, Pilop Christiane, Rothgiesser Karin M, Bigler Martin, Pagani Olivia, von Moos Roger, Weder Patrik, Riniker Salome, Thürlimann Beat
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Hussein K, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Y Brucker S, Bonnefoi H, Curigliano G. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28:1700-1712.
Aug 1, 2017De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Aug 1, 2017Ann Oncol 2017; 28:1700-1712
Xu B, Osborne K C, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Hussein K, Huober J, Huang C-S, Hayes D F, Harbeck N, Pagani O, Partridge A H, Pritchard K, Whelan T J, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E J T, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H J, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Y Brucker S, Bonnefoi H, Curigliano G
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
Bartlett J, Rea D, Dowsett M, Cuzick J, Viale G, Forbes J, Brookes C, Van de Velde C, Putter H, Seynaeve C, Thürlimann B, Dell'Orto P, Mallon E, Sestak I, Regan M, Ahmed I. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. Eur J Cancer 2017; 79:129-138.
May 8, 2017HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
May 8, 2017Eur J Cancer 2017; 79:129-138
Bartlett John M S, Rea Daniel W, Dowsett Mitchell, Cuzick Jack, Viale Giuseppe, Forbes John F, Brookes Cassandra L, Van de Velde Cornelis J H, Putter Hein, Seynaeve Caroline, Thürlimann Beat, Dell'Orto Patrizia, Mallon Elizabeth A, Sestak Ivana, Regan Meredith M, Ahmed Ikhlaaq
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study
Borgquist S, Regan M, Gelber R, Price K, Rabaglio M, Goldhirsch A, Coates A, Smith I, von Moos R, Ejlertsen B, Debled M, Láng I, Colleoni M, Garber J, Ahern T, Giobbie-Hurder A, Thürlimann B. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. J Clin Oncol 2017; 35:1179-1188.
Feb 13, 2017Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study
Feb 13, 2017J Clin Oncol 2017; 35:1179-1188
Borgquist Signe, Regan Meredith M, Gelber Richard D, Price Karen N, Rabaglio Manuela, Goldhirsch Aron, Coates Alan S, Smith Ian, von Moos Roger, Ejlertsen Bent, Debled Marc, Láng István, Colleoni Marco, Garber Judy E, Ahern Thomas P, Giobbie-Hurder Anita, Thürlimann Beat